CRTH2 expression on T cells in asthma by Mutalithas, K et al.
CRTH2 expression on T cells in asthmacei_4161 34..40
K. Mutalithas, C. Guillen, C. Day,
C. E. Brightling, I. D. Pavord and
A. J. Wardlaw
Institute for Lung Health, Department of
Infection Immunity and Inﬂammation,
University Hospitals of Leicester, Leicester, UK
Summary
Mast cell-derived prostaglandin D2 (PGD2) is the major prostanoid found
within the airway of asthmatics immediately following allergen challenge.
PGD2hasbeenshowntohavechemokineticeffectsoneosinophilsandThelper
type2(Th2)cellsinvitro.ThisoccursthroughtheinteractionofPGD2withthe
G-protein-coupled chemokine receptor homologous molecule expressed on
Th2 lymphocytes (CRTH2). The expression of CRTH2 has been shown to
be highly selective for Th2 cells. Using ﬂow cytometry we have studied the
expression of CRTH2 on T cells in blood and bronchoalveolar lavage ﬂuid
inasthmaticsandnormalsubjects.CRTH2expressionwasconﬁnedtoasmall
percentage of blood T cells in asthmatics (1·8%  0·2) and normal (1·6% 
0·2)subjects.CRTH2wasenrichedsigniﬁcantlyoninterleukin(IL)-4
+/IL-13
+T
cells compared to interferon (IFN)-g
+ T cells (P < 0·001). There was a small
populationofCRTH2
+Tcellsinthebronchoalveolarlavage(BAL)ofasthmat-
ics(2·3%  0·6)andnormalsubjects(0·3%  0·1),andtherewasasigniﬁcant
difference between the two groups (P < 0·05). There were similar amounts of
PGD2 in the BAL of asthma and normal subjects. Within paired blood–BAL
samples from the same subject there was no increase in CRTH2
+ T cells in the
BAL compared to blood in asthmatics. Enrichment of CRTH2 on IL-4
+ and
IL-13
+TcellscomparedtoIFN-g
+TcellswasalsoseeninBALfromasthmatics
(P < 0·001). CRTH2 is expressed preferentially by IL-4
+/IL-13
+ T cells com-
paredtoIFN-g
+Tcells.However,giventheirsmallnumberstheyareunlikelyto
have a signiﬁcant involvement in the pathogenesis of asthma.CRTH2 antago-
nism may not diminish T cell accumulation in the asthmatic lung.
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Introduction
Thereleaseofpreformedmediatorsfromresidentlungcellsis
thought to contribute to the typical early asthma response
following allergen encounter. The arachidonic acid metabo-
lite prostaglandin D2 (PGD2) is a lipid mediator known to be
released rapidly by immunoglobulin (Ig)E-activated mast
cells in signiﬁcant quantities upon allergen exposure [1].
Dendritic cells are also known sources of PGD2 [2]. In asth-
matics, large quantities of PGD2 are detected in bronchoal-
veolar lavage ﬂuid within minutes of allergen encounter.
PGD2notonlyexertslocaleffectswithintheasthmaticairway,
butmayalsoplayaroleinrecruitingandactivatingleucocytes
that could then contribute to the late asthma response [3].
The proinﬂammatory effects of PGD2 include induction
of local vasodilatation which also contributes to oedema,
recruitment of eosinophils and T helper type 2 (Th2) cells,
induction of Th2 cytokine synthesis and in asthma causes
bronchoconstriction [4,5]. PGD2 is known to exert its bio-
logical effects via three G-protein coupled receptors; D
prostanoid 1 (DP1), TP (thromboxane A2 receptor) and
the recently characterized receptor CRTH2 (chemokine
receptor homologous molecule expressed on T helper type
2 cells) [3]. Despite their local effects, neither DP1 nor TP
receptor had any effect on inﬂammatory cell activation or
recruitment. The recruitment and activation of eosinophils
and Th2 cells by PGD2 appears to be mediated primarily
via CRTH2 [6]. The CRTH2 receptor also interacts with
many of the PGD2 metabolites, including 15d-PGJ2, which
has an anti-inﬂammatory role [7].
In vitro, activation of CRTH2 (also known as the DP2
receptor) was shown to induce migration of eosinophils [8],
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was shown to exacerbate pathology in a mouse model of
asthma [12] and Ramatroban, a moderate CRTH2 and
strong TP antagonist, was shown to attenuate eosinophil
accumulation into the mouse airway [13]. PGD2 was shown
to induce interleukin (IL)-4, IL-5 and IL-13 production by
Th2 cells in humans via a CRTH2-dependent mechanism
[14]. This effect was also inhibited by Ramatroban.
CytokinesfromTh2cellsarerecognizedtorelatecloselyto
a number of aspects of asthma pathophysiology [15].
CRTH2 has been suggested to be the most reliable marker of
circulating Th2 cells [16]. The selective recruitment of Th2
cells to the airway by mast cell-derived PGD2 acting via
CRTH2 provides a convenient mechanism by which the
innate immune system links with the adaptive immune
response in propagating the inﬂammatory response. Func-
tional polymorphisms of the CRTH2 gene within certain
populations have been linked with severe forms of asthma
[17]. A short-term human asthma study has shown that
treatment with Ramatroban resulted in reduced airway
hyper-responsiveness [18]. In some animal models of
asthma, eosinophil accumulation and IL-5 production was
shown to be enhanced in CRTH2-deﬁcient mice [19];
however,thismaybeexplainedinpartbythefactthatmouse
Th2 cells do not express CRTH2 preferentially.
Given the possible involvement of CRTH2 in asthmatic
inﬂammation and its potential to lead to future pharmaco-
logical intervention,further evidence is needed for the direct
involvement of CRTH2 in human asthma. There have been
nostudiestodatedemonstratingthedirectroleof CRTH2in
the recruitment of Th2 cells in human asthma.Using a com-
mercially available monoclonal antibody (mAb) to CRTH2,
we have studied the role of CRTH2 in T cell recruitment to
the lung in asthma.
Materials and methods
Subjects
A total of 24 subjects with asthma and 20 normal subjects
were included in the study. Patients were recruited from
Glenﬁeld Hospital in Leicester, UK. Subjects were charac-
terized using clinical history and lung function. Asthma
was diagnosed as described previously [20]. Asthma sub-
jects had a suggestive history with recurrent cough, wheeze,
sputum production and either airway hyperresponsiveness
(Pc20 < 8 mg/ml) or reversible airﬂow obstruction [forced
expiratory volume in 1 s (FEV1) > 12%]. Normal subjects
had no history of respiratory disease. Methacholine chal-
lenge was performed using a Wright’s nebulizer and results
are expressed as the provoking concentration of methacho-
line required to elicit a 20% decrease in FEV1 (Pc20).
Atopic status was assessed by measurement of total IgE
concentration and skin prick tests to common aeroaller-
gens (a wheal diameter > 3 mm compared to control was
deﬁned as positive). Subject characteristics are given in
Table 1. Not all subjects had a bronchoscopy. Characteris-
tics of those who had a bronchoscopy are listed separately
within Table 1. The patients in this study are also the
subject of a separate report on CCR8 expression in asthma
(in press).
All but ﬁve asthmatics (mild intermittent asthmatics)
were treated with regular inhaled corticosteroids.Eight asth-
matics were using oral and inhaled corticosteroids. Among
the asthmatics, 12 had refractory asthma according to the
American Thoracic Society (ATS) criteria. Bronchoscopy
was performed on only 11 of the asthmatics and seven
normal subjects. Of the 11 asthmatics investigated with
bronchoscopy,ninehadsevereasthma,andof theseﬁvewere
on oral corticosteroids. The study was approved by the local
ethics committee and written informed consent was
obtained from all participants.
Bronchoscopy
Ten ml of venous blood was obtained prior to the procedure
forisolationof peripheralbloodmononuclearcells(PBMC).
Bronchoscopy was performed using local anaesthesia
according to standard techniques. Asthmatic subjects were
premedicated with 2·5 mg of nebulized Salbutamol 20 min
prior to the procedure. Mild sedation with midazolam was
used in some subjects. Bronchoalveolar lavage (BAL) was
Table 1. Characteristics of all asthmatics and normal subjects who were studied are given in the ﬁrst two columns.
n
Normal Asthma Bronchoscopy normal Bronchoscopy asthma
20 24 7 11
Age
† 30 (19–56) 42 (20–66) 24 (21–49) 44 (36–60)
Male 7 16 3 5
Atopy 6 17 1 4
IgE
‡ (kU/l) 17 (7·2) 513 (190) 101 (34) 613 (322)
FEV1%Pred
‡ 94 (9) 83 (3·9) 100 (6·3) 74 (7·2)
Pc20
§ > 16 1·0 (0·8) > 16 0·6 (0·8)
On OCS 0 8 0 5
Thecharacteristicsof onlythosewhounderwentbronchoscopyaregivenseparatelyinthelasttwocolumns.
†Median(range).
‡Mean(standarderror
of the mean).
§Geometric mean (log standard deviation). FEV1, forced expiratory volume in 1 s; Ig, immunoglobulin; OCS, oral glucocorticosteroids.
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aliquots of 60 ml of warmed sterile 0·9% saline. BAL ﬂuid
was placed into and transported in ice prior to analysis.
Biopsies were ﬁrst ﬁxed in 4% paraformaldehyde and then
embedded in parafﬁn.
Isolation of PBMC and BAL T cells
Heparinized venous blood (10–15 ml) was obtained from all
subjects. PBMC were isolated from whole blood using
density gradient centrifugation (Histopaque 1077; Sigma,
Poole, UK). PBMC were washed and suspended in
phosphate-buffered saline (PBS) (Invitrogen, Paisley,
UK) + 0·5% bovine serum albumin (BSA) (Sigma) during
staining and subsequent ﬂow cytometry. First, BAL samples
were ﬁltered through 48-mmn y l o ng a u z et or e m o v ed e b r i s .
Cells were pelleted and red cell lysis was performed if signiﬁ-
cant blood contamination had occurred. Supernatants were
collected and stored at -80°C for estimation of PGD2.R e d
cell lysis was performed by incubating the cellular pellet with
asmallvolumeof ice-colddistilledwaterfor20 sfollowedby
quenching with a large volume of isotonic PBS.
Flow cytometry
All samples were labelled with anti-CRTH2 and anti-CD3.
Anti-CD4, anti-CD8 (Becton Dickinson Biosciences,
Oxford, UK) and anti-CD45RO (Caltag, Buckingham, UK)
were also used in some samples. PBMC and BAL cells were
incubated with biotinylated anti-CRTH2 mAb (Mitenyi
Biotec, Bergisch Gladbach, Germany) at 4°C while sus-
pended in PBS and 0·5% BSA. Streptavidin–phycoerythrin
(Caltag) was used as the secondary agent. Intracellular
cytokine was studied in some of the samples. Where intrac-
ellular cytokine was studied, cells were ﬁrst incubated with
anti-CRTH2 and then stimulated using 25 ng/ml of phorbol
myristate acetate (PMA) (Sigma) and 500 ng/ml of calcium
ionophore A2317 (Sigma) in the presence of 10 mg/ml
Brefeldin (Sigma) for 6 h at 37°C. Cells were then washed
and ﬁxed using 4% paraformaldehyde before being perme-
abilized with a 0·1% solution of Saponin. Cells were then
stained for intracellular IL-4, IL-13 and interferon (IFN)-g
using directly labelled mAbs followed by CD3-peridinin
chlorophyll (PerCP). Samples were analysed on a ﬂuores-
cence activated cell sorter (FACS) Canto using FACS Diva
software (Becton Dickinson immunocytometry system). At
least 10 000 live cells were acquired from each sample for the
analysis of surface CRTH2. The percentage of CRTH2
+ cells
was estimated within the CD3 gated population. The per-
centages of CD3
+ cells that were cytokine-positive were low,
and on average 30 000–40 000 PBMC, and BAL cells were
analysedfromeachsamplewhenintracellularcytokineswere
studied. Isoytpe controls were included for all tests. Samples
showing non-speciﬁc binding with isotype control (> 0·1%)
were eliminated from analysis.
Prostaglandin D2 enzyme-linked immunosorbent assay
(ELISA)
Detectable quantities of PGD2 were found in BAL samples
from asthma and normal subjects without the need for
concentration. PGD2 was measured in BAL samples using a
commercially available PGD2 ELISA kit [prostaglandin-D2
MOX enzyme immunoassay kit from Cayman Chemicals
(Tallinn, Estonia)]. The detection limit for this product was
6 pg/ml.
Statistical analysis
Subject characteristics are described using descriptive
statistics. Means are expressed together with standard error
of the mean (s.e.m.). Median values were expressed with
interquartile ranges (IQR). Statistical analysis was per-
formed with GraphPad Prism (GraphPad Software Inc.).
Differences between groups were assessed using the Mann–
Whitney U-test. Pearson’s or Spearman’s tests were used to
assess correlation. A P value < 0·05 was considered statisti-
cally signiﬁcant. This was an explorative study and power
calculation had not been possible, as the level and variation
of the expression of CRTH2 in human blood or BAL was not
known.
Results
The percentage of CRTH2
+ T cells in blood was similar
in subjects with asthma and normal controls
Among PBMC, CRTH2 expression was seen mainly on
non-T cells (~3%) (Fig. 1a).The non-T cells were conﬁrmed
as basophils using IgeR1 (results not shown). Only a small
number of CRTH2
+ T cells were seen in blood from asth-
matics(1·8%  0·2)andnormalsubjects(1·6%  0·2),with
no signiﬁcant difference between the groups (two asthma
subjects were not included in the analysis (because of what
appeared to be high levels of non-speciﬁc staining) (Fig. 1b).
The majority were CD4
+ T cells (62·8%  2·1; n = 5).
CRTH2
+ T expression was seen on 30·9%  1·5 (n = 5) of
CD8 T cells. 68%  9·8 (n = 5) were CD45RO
+. Given the
association of CRTH2 with allergy, we also investigated
whether CRTH2
+ T cells were associated with the allergy
serum markers. CRTH2
+ T cell numbers did not show any
signiﬁcant correlation with atopy, serum IgE levels (r2 = 0·2;
P = 0·28) or blood eosinophil numbers (r2 = 0·1; P = 0·5).
CRTH2 is enriched on IL-4 and IL-13 expressing T cells
in blood compared to IFN-g-expressing T cells
The association of blood T cell CRTH2 expression with
intracellular cytokine was studied following in vitro stimu-
lation of PBMC with PMA and calcium ionophore for 6 h.
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+ and
IL-13
+ T cells than IFN-g
+ T cells. In asthma, 26·5%  4·5
and 35·5%  3·3 of the IL-4
+- and IL-13
+-producing T cells
also expressed CRTH2,while only 2·4%  0·5 of IFN-g
+ cells
also expressed CRTH2 (P < 0·001) (Fig. 2a). A similar
pattern of expression of CRTH2 on IL-4
+ and IL-13
+ Tc e l l s
relative to IFN-g
+ T cells was also seen in blood of normal
subjects (Fig. 2b).
There were more CRTH2
+ T cells in the BAL of
asthmatics compared to normal subjects
Although BAL was taken from 12 asthma subjects, one
sample had be eliminated due to very poor quality and non-
speciﬁc staining. There was only a small number of CRTH2
+
T cells in the BAL in both groups. Nevertheless, there was a
signiﬁcantdifferencebetweenthetwogroups(2·3%  0·6in
asthmatics versus 0·3%  0·1 in normal subjects; P < 0·05)
(Fig. 3a). We also compared the percentages of CRTH2
+ T
cellsinpairedbloodandBALsamplesfromthesamesubject.
No signiﬁcant difference was seen in asthmatics; however,
there was a signiﬁcant difference in normal subjects
(0·8%  0·1 in blood versus 0·3%  0·1 in BAL; P < 0·05)
(Fig. 3b).
CRTH2 expression was enriched on IL-4 and IL-13
expressing BAL T compared to IFN-g-expressing T cells
Intracellular cytokine content in BAL T cells was studied in
only ﬁve of the 11 subjects who had BAL samples taken, due
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Fig. 1. (a) Representative ﬂuorescence activated cell sorter (FACS) dot
plots showing association of chemokine receptor homologous
molecule expressed on T helper type 2 (Th2) lymphocytes (CRTH2)
with CD3, CD4 and CD8, and CD45RO. The gates were set with
reference to the isotype control for each antibody. There was no
difference in the degree of staining (mean ﬂuorescence) on
CRTh2-positive T cells from asthmatics and controls. (b) Scatter-plot
of the percentages of CRTH2
+ T cells in blood of normal subjects ()
and asthmatics (). Bars represent the mean. No signiﬁcant difference
in the percentage of CRTH2
+ T cells was seen between the groups.
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Fig. 2. (a) Scatter-plot showing chemokine receptor homologous
molecule expressed on T helper type 2 (Th2) lymphocytes (CRTH2)
expression on () interferon (IFN)-g+,( ) interleukin (IL)-4+ and
() IL-13+ T cells derived from peripheral blood mononuclear cells
(PBMC) from asthmatic subjects. Cells were stimulated for 6 h
with phorbol myristate acetate (PMA) and calcium ionophore.
***P < 0·001 using the Mann–Whitney U-test. Bars represent mean
percentages. (b) Scatter-plot showing CRTH2 expression on ()
IFN-g
+,( )I L - 4
+ and () IL-13
+ T cells derived from PBMC from
normal subjects. Cells were stimulated for 6 h with PMA and calcium
ionophore. ***P < 0·001 using the Mann–Whitney U-test. Bars
represent mean percentages.
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Cells were stimulated with PMA and calcium ionophore for
6 h. In asthmatic subjects CRTH2 was expressed by
17·3%  5·3 of the IL-4
+ cells and 16%  6·4 of the IL-13
+
cells. In contrast, only 1·2%  0·1 of IFN-g
+ cells expressed
CRTH2 (P < 0·01; Fig. 4).The expression of CRTH2 on BAL
T cells from normal subjects was too small for this assess-
ment to be made accurately.
There was no difference in the concentration of PGD2
in BAL between and asthmatics and normal subjects
Although there was no difference in the percentage of
CRTH2
+TcellsbetweenBALandbloodinasthma,therewas
ahigherpercentageof thesecellsinasthmaticBALcompared
to normal controls. We have therefore measured the ligand
for CRTH2, PGD2 in BAL. Although a signiﬁcant difference
was not seen between the two groups,a bimodal distribution
of PGD2 levels was seen within the asthma group (Fig. 5). A
similar distribution was seen with CRTH2
+ T cells in BAL in
asthma (Fig. 3a).We therefore explored whether there was a
correlation between the percentages of CRTH2
+ T cells and
PGD2 within the same BAL sample. Due to the small
numbers,Spearman’s correlation test was used.A signiﬁcant
correlation was not seen (r
2 = 0·4; P = 0·07).
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Fig. 3. (a) Chemokine receptor homologous molecule expressed on T
helper type 2 (Th2) lymphocytes (CRTH2)
+ T cells in bronchoalveolar
lavage (BAL) from asthmatic () and normal () subjects. There was
a signiﬁcant difference between asthmatic and normal controls.
*P < 0·05 using the Mann–Whitney U-test. Bars represent mean
percentages. (b) CRTH2
+ T cells in paired blood ()a n dB A L( )
samples from normal subjects. Lines connect samples from the same
subject. *P < 0·05 using the Mann–Whitney U-test.
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Fig. 4. Scatter-plot of the percentage of chemokine receptor
homologous molecule expressed on T helper type 2 (Th2)
lymphocytes (CRTH2)
+ bronchoalveolar lavage (BAL) T cells from
asthmatic subjects expressing interferon (IFN)-g (), interleukin
(IL)-4 () and IL-13 (). **P < 0·01 using the Mann–Whitney
U-test. Bars represent mean percentages.
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Fig. 5. Levels of prostaglandin D2 (PGD2) in bronchoalveolar lavage
(BAL) ﬂuid from asthmatic () and normal subjects (). Bars
represent mean percentages. No signiﬁcant difference was seen
between the two groups.
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The inﬂammatory process in asthma is considered to be
driven in part by cytokines derived from Th2 lymphocytes
recruited into the airway. The mechanisms controlling
migration of Th2 cells into the airway are therefore of
interest. CRTH2 has been suggested to be a marker for Th2
cells [16]. It binds to the ligand PGD2 known to be released
in large quantities by mast cells in response to allergen expo-
sure [1]. PGD2 has therefore attracted considerable interest
due its potential for recruiting Th2 cells to the asthma lung.
We believe that this is the ﬁrst study to report expression of
CRTH2 on T cells in asthma. We found that CRTH2 is
expressed by a greater percentage of IL-4
+ T cells than IFN-g
+
T cells.However,we found only very low levels of expression
of CRTH2 in both blood and BAL T cells; nevertheless, a
signiﬁcant difference was seen in CRTH2
+ BAL T cells in
asthmatics compared to controls. Asthmatics had a greater
percentage of CRTH2
+ T cells in their BAL than normal
controls.
We found that CRTH2 was expressed by only a small
percentage of blood T cells in asthma (~1·8%) and there was
no difference in the percentage of these cells in blood from
asthma compared to normal subjects. The percentages of
IL-4
+/IL-13
+ T cells in our study also included CD8
+ Tc e l l s
(Tc2). Furthermore, cells in our study were single-stained
with anti-IL-4 or anti-IFN-g, and some of the IL-4
+ Tc e l l s
may also be IFN-g
+ (Th0 cells). Given these limitations, it
would be difﬁcult to suggest a deﬁnite association of CRTH2
withTh2cells.Nonetheless,ourdataprovidesomeevidence
thattheyareassociatedwithTh2cells.CRTH2wasexpressed
on ~8–10-fold higher percentages of IL-4
+ T cells than
IFN-g
+ T cells.
The absolute numbers of IL-4
+ or IL-13
+ T cells that are
CRTH2
+ were small and only one sample was taken from
each subject in our study, but the data for PBMC is from a
reasonable number of subjects and the range of expression
small, so we feel the lack of a difference between asthmatics
and normal subjects is a robust ﬁnding. The small numbers
of patients included for BAL analysis is a limitation of the
study but,again,the spread of the data is small,demonstrat-
ing that the low-level expression seen is a consistent ﬁnding.
The expression of CRTH2 on BAL T cells in asthma has
the appearance of being bimodal. While this could be an
artefact of the small numbers of subjects and there was no
signiﬁcant correlation between BAL PGD2 concentrations
and the percentage of BAL CRTH2 cells, the ﬁve subjects
withinthegroupwhohadlownumbersof CRTH2
+Tcellsin
BAL also had lower levels of PGD2 (< 500 pg/ml). This may
indicate that the PGD2 may be playing a role in recruiting
CRTH2
+ T cells to the lung in some asthmatics. Some of the
asthmatics were taking oral corticosteroids; however, there
was no signiﬁcant difference in the percentages of BAL
CRTH2
+ T cells or PGD2 levels between this group and those
not on oral corticosteroids.
We did not see a signiﬁcant increase in CRTH2
+ T cells in
BAL compared to blood within the same subject. In fact, in
the normal group there was a lower percentage of CRTH2
expressing T cells in the BAL compared with blood. We
cannot explain this readily. It is possible that this could be
due to down-regulation of the receptor due to interaction
with PGD2 in the lung, or could be related to more activated
cells being present in the lung. However, only low levels of
PGD2 would be expected to be present in the normal lung,
and we have shown that short-term activation with PMA
and calcium ionophore did not affect expression of CRTH2
(data not shown).
PGD2 has been shown to be able to modulate T cells
locally and encourage Th2 cell polarization through interac-
tion with the DP1 and CRTH2 receptor [3]. The DP1 recep-
tor is expressed mainly by Th1 cells, and its interaction with
PGD2 results in the inhibition of cytokines by these cells.
CRTH2,ontheotherhand,hasbeenshowntobeinvolvedin
the induction of cytokines by Th2 cells [14]. CRTH2
+ Tc e l l s
were shown to be able to produce more PGD2, providing an
autocrine ampliﬁcation mechanism. It has been suggested
that PGD2, by acting on DP1 and CRTH2 receptors, could
drive a state of Th2 polarization within the tissue [14].
However, given the small number of CRTH2
+ c e l l sw eh a d
observed among BAL T cells, it would seem unlikely for
CRTH2 to have a signiﬁcant functional role in modulating T
cells in asthma pathogenesis.
CRTH2 has been suggested to be the most reliable
marker for circulating human Th2 cells [16]. In this study
~26% of IL-4
+ T cells and ~35% of IL-13
+ T cells in blood
expressed CRTH2 compared to ~2% of IFN-g
+ T cells, indi-
cating a degree of speciﬁcity for IL-4
+/IL-13
+ T cells. In a
previous study we have shown that ~40% of IL-4
+ blood
and BAL T cells express CCR4; however, in the same study
~15% of IFN-g
+ T cells also expressed CCR4, which may
suggest that CCR4 is less speciﬁc than CRTH2 as a marker
for IL-4
+ T cells [21]. The downside for CRTH2 as a Th2
marker in asthma is that its expression was seen in only
~17% of IL-4
+ T cells in the BAL of asthmatics. Conversely,
we have shown that ~30% of IL-4
+ T cells in the BAL of
asthmatics express CCR8, and this receptor also showed a
similar degree of speciﬁcity for Th2 cells as CRTH2 (paper
under submission).
In summary,although we found a signiﬁcant difference in
the percentage of CRTH2
+ T cells in the lung between asth-
matics and normal subjects, the percentage of these cells in
BAL in both groups is very low. It is therefore difﬁcult to
conclude whether they have a signiﬁcant biological role in
the pathogenesis of asthma. There was no evidence of
enrichmentof CRTH2withinthelungcomparedtobloodin
asthmatics or normal subjects, and furthermore we had not
been able to demonstrate a difference in the level of PGD2 in
the BAL ﬂuid between asthmatics and normal controls. Our
data therefore do not provide evidence to support CRTH2
playing a role in recruiting T cells to the lung.
CRTh2 in asthma
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